Latest News and Press Releases

Dose escalation ongoing in Phase 1/1b trials evaluating two RAS(ON) Inhibitor drug candidates, RMC-6236 (RASMULTI inhibitor) and RMC-6291 (KRASG12C inhibitor) Completed successful equity financing to...

Lead RAS(ON) Inhibitor drug candidates RMC-6236 (RASMULTI) and RMC-6291 (KRASG12C) approaching the clinic RMC-4630-03 Phase 2 trial evaluating RAS Companion Inhibitor RMC-4630 (SHP2) in combination...

REDWOOD CITY, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...

RAS(ON) Inhibitor Development Candidates Targeting KRASG12C and RASMULTI Progressing Toward the Clinic; Company Showed Additional Preclinical Data Supporting Benefits and Differentiation Company...

REDWOOD CITY, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit...

Multiple AACR Presentations Highlight Potential Advantages of RAS(ON) Inhibitors; Scientific Publication is First to Demonstrate Anti-Drug Resistance Features Continued Advancement and Enrollment of...

REDWOOD CITY, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...

Advanced and Expanded Portfolio of RAS(ON) Inhibitors; Two Assets Entered IND-Enabling Development Continued Progress in Development of RAS Companion Inhibitors to Support Targeted Combination...

REDWOOD CITY, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD) today announced that it has commenced an underwritten public offering of 4,000,000 shares of common...

REDWOOD CITY, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...